New study tracks Ocrelizumab's impact on MS brain fluid markers
NCT ID NCT04466150
First seen Jan 26, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study looks at how the drug ocrelizumab changes certain markers in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis or a high-risk first episode. Thirty participants will receive ocrelizumab and have their spinal fluid tested before and after three years of treatment. The goal is to see if the drug reduces signs of long-term inflammation in the brain and spine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California San Francisco
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.